Single Injection Technique Prolotherapy for Hypermobility Disorders of TMJ Using 25 % Dextrose: A Clinical Study

Majumdar, Swapan Kumar; Krishna, Shreya; Chatterjee, Aritra; Chakraborty, Rajib; N, Ansari

doi:10.1007/s12663-016-0944-0

Cited by 18 publications

(22 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27,28 Pericapsular fibrosis, after pericapsular injection around the TMJ, has been suggested by pre-and post treatment magnetic resonance imaging data. 23 Although proliferation is potentially helpful in conditions associated with degenerative extra-and intra-articular tissues, it may not be the primary mechanism of change in the present study. We selected an intraarticular protocol to avoid such potential effects, which could further limit the range of motion associated with mouth opening.…”

Section: Discussionmentioning

confidence: 83%

“…The direction and scale of these results are generally consistent with those of other reports of DPT for TMD and other musculoskeletal pain conditions. 11,20 One retrospective case series, 21 3 prospective case series, 14,22,23 and 2 RCTs 12,24 have reported favorable clinical outcomes of DPT for TMD, measured as a marked subjective reduction in episodes of painful subluxation. However, only 1 prospective case series and 1 RCT used a quantifiable pain measure (visual analog scale or NRS) as well as a measure of MIO (in millimeters), pre-and posttreatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection (Prolotherapy): A Randomized Controlled Trial With Long-term Partial Crossover

Louw

Reeves²,

Lam

et al. 2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Objective: To assess the efficacy and longer-term effectiveness of dextrose prolotherapy injections in participants with temporomandibular dysfunction. Patients and Methods: A randomized controlled trial with masked allocation was conducted from January 14, 2013, through December 19, 2015. Forty-two participants (with 54 joints) meeting temporomandibular dysfunction criteria were randomized (1:1) to 3 monthly intra-articular injections (20% dextrose/0.2% lidocaine or 0.2% lidocaine) followed by as-needed dextrose/0.2% lidocaine injections through 1 year. Primary and secondary outcome measures included a 0 to 10 Numerical Rating Scale score for facial pain and jaw dysfunction; maximal interincisal opening (MIO) measured in millimeters, percentage of joints with 50% or more change (improvement) in pain and function, and satisfaction.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection (Prolotherapy): A Randomized Controlled Trial With Long-term Partial Crossover

Louw

Reeves²,

Lam

et al. 2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…MMO did not show any statistical significant reduction in their study. Majumdar et al reported an overall success rate of 91.3% in a sample of 23 patients after a mean follow‐up period of 13.9 months. They tried to limit the number of dextrose injections, but only seven patients (30.4%) were successfully managed by a single injection while two injections were required in 8 (34.7%) and three injections were required in six patients (26.1%) for managing hypermobility.…”

Section: Discussionmentioning

confidence: 98%

“…Pathogenesis of TMJ hypermobility is commonly associated with trauma, abnormal chewing movements, poor development of the articular fossa, weakness or laxity of the TMJ ligament and joint capsule, and excessive activity of the lateral pterygoid and infrahyoid muscles due to drugs such as phenothiazine or diseases characterised with general joint laxity (Ehlers‐Danlos syndrome, Marfan syndrome and juvenile rheumatoid arthritis) …”

Section: Introductionmentioning

confidence: 99%

The efficacy of dextrose prolotherapy over placebo for temporomandibular joint hypermobility: A systematic review and meta‐analysis

Nagori¹,

Jose

Venkatesan

et al. 2018

J of Oral Rehabilitation

View full text Add to dashboard Cite

Within the limitations of the study, dextrose prolotherapy may cause significant reduction in mouth opening and pain associated with TMJ hypermobility. Conclusions with regard to reduction of episodes of subluxation/dislocation cannot be drawn. There is a need of more high-quality RCTs with larger sample size and homogenous prolotherapy protocol to draw stronger conclusions on the effect of dextrose prolotherapy in patients with TMJ hypermobility.

show abstract

“…Except for the duration of complaints, the subjects' characteristics would match with most of the reported publications. In my study, the duration of symptoms was maximumally 48 month (Mean of 24 m ± 11.4) while patients in other studies reported longer period of symptoms[17,22,23]. In the current study, patients reported a pain intensity that ranged between 5-10 on visual analogue scale.…”

mentioning

confidence: 40%

Prolotherapy with 12.5% dextrose to treat temporomandibular joint dysfunction (TMD)

Shehata¹

2019

Int J Oral Craniofac Sci

View full text Add to dashboard Cite

Introduction: Temporomandibular joint dysfunction (TMD) is a collective term used to describe a complex and multifactorial disorders of the orofacial region. Symptoms commonly associated with TMD include TMJ pain, limited mandibular movement or locking and painful clicking or popping sounds. Most of patients diagnosed with TMD are initially treated conservatively. Failure of such conservatism poses a great challenge for the treating physician. Prolotherapy has been used successfully in many joints in the body by orthopedics and spinal surgeons. Injection prolotherapy has also been used in management of weakening tendons or ligaments in head and neck. Aim of the study: To evaluate the effi cacy of dextrose prolotherapy with 12.5% concentration in the treatment of intractable temporomandibular joint dysfunction. Material & Methods: A prospective clinical study with 33 patients with the diagnosis of TMD were included in this study during the period from Jan. 2012 to Jan.2015. Inclusion criteria were; adult patients above 18 years old, with TMD symptoms for more than 6 months, had failed conservative treatment and have no pathological fi ndings on dynamic magnetic resonance imaging. Prolotherapy was achieved by six sessions of 12.5% dextrose (3ml) injection per joint with one month interval. A Semi-structured questionnaire developed by the author was utilized to gather all demographic data. All variables were collected, tabulated and analyzed. Follow up appointments were booked after the last session, every 3 months for up to 24 month. Results: I used maximum mouth opening, clicking and visual analogue pain score to judge the effi cacy of my protocol. There was statistical signifi cant improvement of all previous variables outcomes. Conclusion: Dextrose prolotherapy can be used in patients diagnosed with TMD whom had failure of conservative treatment to control their symptoms. More than four prolotherapy sessions is not recommended as per results of this study. It is safe and effi cient technique.

show abstract

Single Injection Technique Prolotherapy for Hypermobility Disorders of TMJ Using 25 % Dextrose: A Clinical Study

Abstract: Hence the use of 25 % dextrose as a proliferant to treat hypermobilty disorders of the TMJ is recommended by us as a first line treatment option as it is safe, economical and an easy procedure associated with minimal morbidity.

Cited by 18 publications

References 11 publications

Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection (Prolotherapy): A Randomized Controlled Trial With Long-term Partial Crossover

Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection (Prolotherapy): A Randomized Controlled Trial With Long-term Partial Crossover

The efficacy of dextrose prolotherapy over placebo for temporomandibular joint hypermobility: A systematic review and meta‐analysis

Prolotherapy with 12.5% dextrose to treat temporomandibular joint dysfunction (TMD)

Contact Info

Product

Resources

About